Physician profile
Stuart Coldsnow
NPI 1265056568
$7,921.08
in general payments reported to CMS, 2019-2025
24 companies · $1,435 in 2025
The $1,435 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,828 · 2022: $1,333 · 2023: $1,790 · 2024: $1,534 · 2025: $1,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,654 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,653.65 |
| Education | $106.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,485.26 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,145.73 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $654.81 | 2021-2025 | Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $636.85 | 2021-2025 | Caplyta |
| Lundbeck LLC | $598.81 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $584.71 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $465.20 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $391.63 | 2021-2025 | Trintellix |
| Alkermes, INC. | $349.22 | 2021-2025 | Lybalvi, Aristada |
| Corium, LLC | $289.82 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $224.13 | 2023-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $198.25 | 2023-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $179.78 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $160.50 | 2022-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $143.83 | 2022-2024 | Jornay Pm |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $96.26 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $76.04 | 2022-2025 | Spravato, Invega Sustenna |
| Tris Pharma INC | $68.90 | 2023-2024 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $68.10 | 2021 | |
| Indivior INC. | $44.09 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $15.77 | 2021 | |
| Eisai INC. | $15.10 | 2021 | |
| Adlon Therapeutics L.P. | $14.79 | 2021 | |
| Collegium Pharmaceutical, INC. | $13.50 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Coldsnow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.